Glaukos Stock Has The Bull Case Changed After Higher 2026 Sales Guidance

• Glaukos raised its 2026 sales guidance to a range of $680 million to $700 million, with iDose TR and Epioxa cited as key contributors alongside a broader ophthalmology portfolio.
• The updated outlook highlights how Glaukos is spreading its revenue base across multiple glaucoma, corneal, and retinal programs rather than relying on a single flagship product.
• This article examines how Glaukos' higher 2026 sales guidance reshapes the investment narrative built around its diversified ophthalmology platform.

See how Glaukos compares with other ophthalmology and specialist healthcare companies by reviewing our hand picked 35 healthcare AI stocks that could also be shaping the next wave of eye care treatments.

Glaukos Investment Narrative Recap

To own Glaukos, you need to be comfortable backing an ophthalmology platform rather than a single product story. The raised 2026 sales guidance to US$680 million to US$700 million leans on iDose TR, Epioxa and a broader glaucoma and corneal toolkit. That update supports the idea that the commercial engine is broadening, not narrowing.

In the near term, the key swing factor remains commercial execution around iDose TR adoption and the Epioxa transition. The biggest operational risk still sits with reimbursement decisions, procedure volume trends and any delay or hiccup in product rollouts. The guidance lift does not remove those issues; it indicates that they are currently being managed.

The upcoming third quarter 2026 results release on 28 October is the next significant checkpoint for this new guidance. Management has already set expectations with the higher 2026 sales range, so the call will likely focus on how iDose TR utilization, payer coverage and early Epioxa traction compare with that outlook.

For you as a shareholder, that update should help clarify whether Glaukos is converting pipeline breadth into consistent commercial performance or relying primarily on a few early wins. Any commentary on reimbursement trends, procedure patterns and spending levels for R&D and commercial build out will matter just as much as the headline revenue number.

Glaukos' current analyst narrative points to revenues of US$1.2b and earnings of US$132.4 million by 2029, based on an assumed 24.9% yearly revenue growth rate and a shift from today’s earnings loss of US$188.0 million to that future profit level. This represents an earnings increase of about US$320 million by the 2029 forecast year.

Uncover why Glaukos' fair value indicates a 14% potential upside to its current price, which could materialize faster than many investors expect.

Exploring Other Perspectives

One alternate view fixates on Epioxa as the real swing factor. The most optimistic analysts were already modeling about US$1.5b of revenue and US$221.4 million of earnings by 2029 before this guidance change, which is far above consensus. You can treat this new sales update as a fresh test of those higher expectations.

Explore 3 other Glaukos fair value estimates, including one that suggests potential upside of as much as 118% from the current price.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Glaukos. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Glaukos' overall financial health at a glance.

Looking For More Investment Ideas Beyond Glaukos?

If Glaukos has sharpened your interest in specialist healthcare, it can help to widen the lens and compare it with other opportunities that fit different risk and return profiles. The Simply Wall St Screener offers a way to do that quickly by filtering the market down to a shortlist that matches your preferences.

• For investors who care most about quality at a reasonable entry point, consider starting with a 29 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect them.
• If resilience is your priority, focus on a 31 resilient stocks with low risk scores that screens for businesses with steadier risk profiles that may better suit a more defensive approach.
• Those who want strength in the balance sheet above all else can narrow the field with a list of solid balance sheet and fundamentals (25 results) and focus research time on companies with financial cushions already in place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com